Martinelli I (2001) Risk factors in venous thromboembolism. Thromb Haemost 86(07):395–403

Article  CAS  PubMed  Google Scholar 

Castoldi E et al (2021) Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon). J Thromb Haemost 19(5):1186–1199

Article  CAS  PubMed  Google Scholar 

Elkattawy S et al (2022) Prothrombin G20210A gene mutation-induced recurrent deep vein thrombosis and pulmonary embolism: case report and literature review. J Investig Med High Impact Case Rep 10:23247096211058486

Article  PubMed  PubMed Central  Google Scholar 

Emmerich J et al (2001) Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost 86(09):809–816

Article  CAS  PubMed  Google Scholar 

Poort SR et al (1996) A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis

Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet (London England) 346(8983):1133–1134

Article  CAS  PubMed  Google Scholar 

Rosendaal F, Reitsma P (2009) Genetics of venous thrombosis. J Thromb Haemost 7:301–304

Article  CAS  PubMed  Google Scholar 

Kujovich JL (2011) Factor v Leiden Thrombophilia. Genet Sci 13(1):1–16

CAS  Google Scholar 

Rosen E et al (1999) High frequency of factor V Leiden in a population of Israeli arabs. Thromb Haemost 82(12):1768–1768

Article  CAS  PubMed  Google Scholar 

Zivelin A et al (1998) A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood J Am Soc Hematol 92(4):1119–1124

CAS  Google Scholar 

Gómez-Outes A et al (2012) Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol 9(2):83–104

Article  PubMed  Google Scholar 

Zöller B et al (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Investig 94(6):2521–2524

Article  PubMed  PubMed Central  Google Scholar 

Ryu J et al (2024) Thrombosis risk in single-and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood 143(23):2425–2432

Article  CAS  PubMed  Google Scholar 

Ho WK et al (2006) Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 166(7):729–736

Article  CAS  PubMed  Google Scholar 

Simioni P et al (2000) Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood J Am Soc Hematol 96(10):3329–3333

CAS  Google Scholar 

Agnelli G et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808

Article  CAS  PubMed  Google Scholar 

Chen A, Stecker E, Warden BA (2020) Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Association 9(13):e017559

Article  CAS  Google Scholar 

Investigators E (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510

Article  Google Scholar 

Investigators H-V (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415

Article  Google Scholar 

Schulman S et al (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 336(6):393–398

Article  CAS  PubMed  Google Scholar 

Schulman S et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352

Article  CAS  PubMed  Google Scholar 

Arora P et al (2017) Use of direct oral anticoagulants in inherited Thrombophilia. Blood 130:3724

Google Scholar 

Skelley JW, White CW, Thomason AR (2017) The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis 43(1):24–30

Article  CAS  PubMed  Google Scholar 

Zuk J et al (2021) Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study. Int J Hematol 113:190–198

Article  CAS  PubMed  Google Scholar 

van Es N et al (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood J Am Soc Hematol 124(12):1968–1975

Google Scholar 

Pikovsky O et al (2020) Congenital thrombotic thrombocytopenic purpura in a large cohort of patients carrying a novel mutation in ADAMTS13 gene. Thromb Res 185:167–170

Article  CAS  PubMed  Google Scholar 

Ageno W et al (2013) The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 11(8):1597–1602

Article  CAS  PubMed  Google Scholar 

Konstantinides SV et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J 41(4):543–603

Article  PubMed  Google Scholar 

Kaatz S et al (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119–2126

Article  CAS  PubMed  Google Scholar 

Rosendaal F et al (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(03):236–239

Article  CAS  PubMed  Google Scholar 

Al-Otaiby M et al (2021) The prevalence of Factor V Leiden (Arg506Gln) mutation in King Khalid University Hospital patients, 2017–2019. Nagoya J Med Sci 83(3):407

CAS  PubMed  PubMed Central  Google Scholar 

Margaglione M et al (2020) Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. Blood Transfus 18(6):486

PubMed  PubMed Central  Google Scholar 

Serrao A et al (2019) Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterranean J Hematol Infect Dis, 11(1)

Undas A, Goralczyk T (2017) Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinolysis 28(6):438–442

Article  CAS  PubMed  Google Scholar 

Campello E et al (2020) Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Association 9(23):e018917

Article  CAS  Google Scholar 

Coleman CI et al (2018) Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. Thromb Res 163:132–137

Article  CAS  PubMed  Google Scholar 

Elsebaie MA et al (2019) Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost 17(4):645–656

Article  PubMed  Google Scholar 

Giustozzi M et al (2019) Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thr